Literature DB >> 25447703

Early prediction of severe acute pancreatitis by urinary β-2 microglobulin/saposin B peak ratios on MALDI-TOF.

Chiz-Tzung Chang1, Hsin-Yi Liao2, Wen-Hsin Huang3, Shih-Yi Lin1, Tsung-Yu Tsai4, Chao-Yuh Yang5, Fuu-Jen Tsai6, Chao-Jung Chen7.   

Abstract

The current methods for predicting severe acute pancreatitis (severe AP) are either complicated or lack efficient sensitivity and specificity. In this study, a simple and practical approach was developed to predict severe AP by using peak intensity ratio of urinary β-2 microglobulin (B2M) to saposin B (SB) on MALDI-TOF MS. Patients with B2M/SB ratio higher than 1.127 present severe AP symptom with a higher Ranson score, computed tomography (CT) grade and longer hospitalization with a sensitivity of 83.7% and specificity of 74.3%. Label-free quantitative proteomics by nanoLC-MS/MS was applied to urine of severe AP patients and found that severe AP is accompanied with kidney injury and inflammation. The measurement of B2M/SB ratios by MALDI-TOF MS could be a simple, accurate and rapid method to diagnose severe AP as well as to monitor AP progression.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; Label-free; Mass spectrometry; Quantitative proteomics; Severe acute pancreatitis

Mesh:

Substances:

Year:  2014        PMID: 25447703     DOI: 10.1016/j.cca.2014.11.019

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  2 in total

1.  Factors associated with pancreatic infection in patients with severe acute pancreatisis.

Authors:  Chen Zou; Zipeng Lu; Zhiqiang Zhang; Liangtao Zhao; Lei Tian; Kuirong Jiang; Yi Miao
Journal:  Int J Clin Exp Med       Date:  2015-08-15

2.  Urine proteome analysis by C18 plate-matrix-assisted laser desorption/ionization time-of-flight mass spectrometry allows noninvasive differential diagnosis and prediction of diabetic nephropathy.

Authors:  Chao-Jung Chen; Wen-Ling Liao; Chiz-Tzung Chang; Hsin-Yi Liao; Fuu-Jen Tsai
Journal:  PLoS One       Date:  2018-07-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.